about
Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patientProcalcitonin to guide antibiotic therapy in the ICUFrench Intensive Care Society, International congress - Réanimation 2016Proceedings of Réanimation 2017, the French Intensive Care Society International CongressLow titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection.Characterization of pandemic influenza immune memory signature after vaccination or infection.Antibiotic stewardship in the intensive care unit.Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome: single-centre experience with 1-year follow-up.Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.What is the niche for extracorporeal membrane oxygenation in severe acute respiratory distress syndrome?Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS.Serotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty Zucker rat.Early High-Volume Hemofiltration versus Standard Care for Post-Cardiac Surgery Shock. The HEROICS Study.Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia.Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomesRecombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature reviewUse of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis.A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia.Prognostic value of procalcitonin in respiratory tract infections across clinical settings.Impact of antibiotic-resistant bacteria on the outcome of ventilator-associated pneumonia.Use of quantitative cultures and reduced duration of antibiotic regimens for patients with ventilator-associated pneumonia to decrease resistance in the intensive care unit.New diagnostic and prognostic markers of ventilator-associated pneumonia.Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infectionsRole of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapyViral infections in the ICU.Aerosolized antibiotics to treat ventilator-associated pneumonia.Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock.Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.Life-threatening massive pulmonary embolism rescued by venoarterial-extracorporeal membrane oxygenation.Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired or ventilator-associated pneumonia.Diagnostic techniques and procedures for establishing the microbial etiology of ventilator-associated pneumonia for clinical trials: the pros for quantitative cultures.Value of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumonia.Out-of-hospital extra-corporeal life support implantation during refractory cardiac arrest in a half-marathon runner.Biomarkers to optimize antibiotic therapy for pneumonia due to multidrug-resistant pathogens.Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an update.White matter changes in comatose survivors of anoxic ischemic encephalopathy and traumatic brain injury: comparative diffusion-tensor imaging study.What role do viruses play in nosocomial pneumonia?Could the DiversiLab® semi-automated repetitive-sequence-based PCR be an acceptable technique for typing isolates of Pseudomonas aeruginosa? An answer from our experience and a review of the literature.The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission.
P50
Q26752680-4564EAF2-1705-4753-87F8-5B6A2A9F9A70Q26775450-FF64A44F-B5D6-4728-848C-8610439E7D15Q28550357-D03FBFE3-CF8A-43CE-91B9-CCE974A3D7A0Q28564101-13546F2F-2FF1-4678-8558-86531F1D7010Q30360402-74B6F944-89E5-4864-8039-86EB66573AB6Q30363416-75400608-24D8-4F15-A11C-19E5EACDE157Q30408712-2B1CB7BB-5335-44C3-A993-D70F5CC516D9Q30411488-DC89B622-538E-4666-BDFC-A207D92FD1EEQ30413369-3176A660-1759-4A8E-81FD-BB706406E3C8Q30420593-22FB83B8-D691-4D9D-9577-6F8163AF36A9Q30420961-A6BA626C-54B2-48A0-A6D1-78F7A26A8026Q33184945-9DC13863-EFE5-4A74-B77D-9FBFBA5ECF6AQ33424340-3A9FBD89-88E5-40E3-A106-4C10D56DAFE9Q33612643-EFEA2D5B-F7B9-4AA5-A0A5-D9F51A241712Q33754176-C4FF23BC-DD63-41C1-AE90-C820C78076F8Q33754446-4EBB034D-EF7E-49E5-9358-490AF37AC7E5Q34020982-CB862A19-66C3-4971-BF13-34B14DF1F2D8Q34264291-17A50952-5B38-4943-AD5F-70C9EC04ECA5Q34455145-34835303-8B59-403B-B480-A7DBBD820100Q35247489-FE7F1FCB-3499-4066-8FD2-5EA552D90D07Q36410119-9C891509-92ED-433B-AF01-7C31DD8AAEC7Q36559379-1C2C757F-1E4C-4F05-B0E4-FD28E92CF08DQ36582154-F2A73A3C-D42D-4BCF-9867-F03F9C941CEEQ37004095-E3EAD919-F2AB-4E60-A6BD-0A851BD1B2F0Q37028474-3A0A01DF-BD0F-446E-A5B3-F573A27DACDFQ37267181-9A48F183-9FFF-4270-B490-0DAD730D1D91Q37412132-20E4AD3A-ED8E-47C4-9594-F945D2B4F04BQ37447019-B9DA6AE6-207E-40BB-8D6D-B944B6DD884DQ37643662-F322FCF8-BE43-4FB3-BA78-C0071329B892Q37724757-AF0BF19F-BDA0-4ADD-A277-A16AFE3D92B3Q37769544-B539E1A2-D368-49CE-BFFC-736E663BB719Q37769548-A5F3C4A1-711D-4F67-A724-55BDC1F2FD97Q37867057-5A2264F0-1B6B-4066-B2A0-1F3D6906F253Q37871170-CBAC4706-B744-48CF-9500-8768538BB97BQ37922284-792E1A18-9918-4C87-8232-9DE6F97B729EQ38102781-C0DB288A-2459-4815-A012-EC0EE79B746EQ38182635-EE2671AC-1B98-48AD-A049-70BBC890AA50Q38184882-1ABC86B1-121D-4B8A-9FE2-52E25F1783C5Q38605820-1F6A280B-D9EF-463E-81C9-41B12B1A056BQ38670151-8CBA55E2-40F0-4824-90AA-B5C20D424857
P50
description
onderzoeker
@nl
name
Charles-Edouard Luyt
@ast
Charles-Edouard Luyt
@en
Charles-Edouard Luyt
@es
Charles-Edouard Luyt
@sl
type
label
Charles-Edouard Luyt
@ast
Charles-Edouard Luyt
@en
Charles-Edouard Luyt
@es
Charles-Edouard Luyt
@sl
prefLabel
Charles-Edouard Luyt
@ast
Charles-Edouard Luyt
@en
Charles-Edouard Luyt
@es
Charles-Edouard Luyt
@sl